Drug induced cardiotoxicity market in 2023 was $1.3B USD, while anti-cancer market is near $150B USD. Where is the value for cardioprotection?
The value is in the anti-cancer efficacy, which is why compounds like dexrazoxane really aren't worth anything. It's anti-cancer effects first and foremost, then cardioprotection thereafter.
Anti-cancer drugs with novel mechanisms of action drive multi-billion dollar buyouts, not cardioprotective agents. All you need to do is show me a multi-billion dollar cardioprotection buyout example.
Drug induced cardiotoxicity market in 2023 was $1.3B USD, while...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.055(3.62%) |
Mkt cap ! $268.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $106.0K | 67.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 649 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |